Immunocore Holdings plc

Immunocore Holdings plc is a commercial-stage biotechnology company built around its proprietary ImmTAX platform, which engineers TCR-based medicines to redirect the immune system against cancer, infectious diseases, and autoimmune disease. Its first approved product, KIMMTRAK, is marketed for unresectable or metastatic uveal melanoma, while the rest of the pipeline remains in clinical and preclinical development.

−10,6 %

98,7 %

−8,9 %

+29,0 %

4.04

4.01

— Immunocore Holdings plc
%
Commercial oncology product100% Approved therapy sold to treat unresectable or metastatic uveal melanoma.
Clinical-stage oncology pipeline0% Investigational TCR-based cancer programs aimed at expanding beyond KIMMTRAK.
Infectious disease pipeline0% Clinical programs targeting chronic viral disease, including hepatitis B.
Autoimmune discovery pipeline0% Preclinical programs designed to extend the platform into autoimmune disease.

Immunocore sells primarily to distributors, hospitals, and healthcare providers that administer KIMMTRAK to eligible...

  • U.S. oncology treatment centersprimary

    Hospitals and specialty clinics in the United States that buy KIMMTRAK for eligible mUM patients and drive the largest revenue base.

  • European distributors and providersprimary

    Regional distributors and healthcare providers in Europe that purchase and dispense KIMMTRAK under local reimbursement systems.

  • International commercial partnerssecondary

    Partners such as Medison and Er-Kim that commercialize KIMMTRAK in selected territories outside core markets.

  • Clinical trial investigators and sitessecondary

    Research centers enrolling patients in PRISM-MEL-301 and HBV studies to advance the pipeline toward approval.

The company is headquartered in the United Kingdom, with principal offices in Abingdon and U.S...

  • •Headquartered in the United Kingdom with U.S. operating offices
  • •Revenue is concentrated in the United States and Europe
  • •KIMMTRAK is launched in 30 countries and approved in 39 countries
  • •Manufacturing is outsourced to CMOs in Denmark and Germany
  • •Global packaging, labeling, and distribution run through the Netherlands
  • •Partner-led expansion covers Canada, Australia, MENA, and CIS regions

Immunocore is focused on expanding KIMMTRAK adoption in existing markets while adding new country launches through...

01
Expand KIMMTRAK commercializationshort-term

KIMMTRAK is the only revenue-generating asset and funds the broader platform.

02
Advance late-stage oncology developmentmedium-term

New oncology approvals would broaden the addressable market beyond uveal melanoma.

03
Build a multi-therapeutic pipelinelong-term

Diversification reduces single-product dependence and improves long-term optionality.

The company remains highly dependent on KIMMTRAK, so any slowdown in uptake, reimbursement, or supply would have an...

high

Single-product revenue concentration

KIMMTRAK is the only marketed product and funds most of the business.

Scope
Commercial revenue and cash generation
Materiality
high
high

Clinical development failure

Pipeline assets may not show sufficient efficacy or safety to reach approval.

Scope
PRISM-MEL-301, HBV, PRAME and autoimmune programs
Materiality
high
high

Manufacturing and supply disruption

Production is outsourced to third-party CMOs and depends on compliant scale-up.

Scope
Drug substance, drug product, packaging and distribution
Materiality
high
high

Capital needs and dilution

The company may need external funding before pipeline assets become commercial.

Scope
R&D and commercialization funding
Materiality
high
medium

International regulatory and geopolitical exposure

Operations, suppliers, and trials span multiple jurisdictions with changing rules.

Scope
UK, EU, U.S., and partner territories
Materiality
medium
Revenue deductions reserve estimation
A 20% change in estimated rebate/chargeback rates moved quarterly revenue by about $1.7 million
Consignment and delivery timing
Can shift revenue between quarters depending on distributor inventory movements
Pricing negotiations in Europe
Can create one-time changes in reported revenue and margins
Tax loss carryforwards and valuation allowance
Deferred tax assets may remain partially or fully reserved

Immunome Inc.

IMNM · Pharmaceutical Preparations

IMMUNIC, INC.

IMUX · Pharmaceutical Preparations

Imunon, Inc.

IMNN · Pharmaceutical Preparations

IMAC Holdings, Inc.

BACK · Services-Specialty Outpatient Facilities, NEC

electroCore, Inc.

ECOR · Electromedical & Electrotherapeutic Apparatus

Immunovant, Inc.

IMVT · Biological Products, (No Diagnostic Substances)

: 28.4.2026